Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOLENE AP-65 vs CO-GESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DOLENE AP-65 is a combination of dipyrone (metamizole) and propantheline. Dipyrone is a non-opioid analgesic and antipyretic that acts centrally and peripherally via inhibition of cyclooxygenase and activation of the endocannabinoid system. Propantheline is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing gastrointestinal motility and spasm.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Pain relief (visceral, colicky),Postoperative pain,Fever reduction
FDA: Management of moderate to moderately severe pain where an opioid is appropriate.,Off-label: Not commonly used off-label; may be considered for refractory pain conditions.
DOLENE AP-65 (propoxyphene napsylate 100 mg and acetaminophen 650 mg). Adult: 1 tablet orally every 4 hours as needed for pain. Maximum: 6 tablets per day.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
2-3 hours in adults with normal hepatic function; prolonged in hepatic impairment (up to 5-10 hours) and in neonates (up to 3-5 hours)
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Dipyrone is metabolized primarily in the liver via CYP450 enzymes (CYP2C9, CYP2C19) to active metabolites (4-methylaminoantipyrine and 4-aminoantipyrine). Propantheline is metabolized hepatic via ester hydrolysis and conjugation.
Hydrocodone: primarily hepatic via CYP3A4-mediated N-demethylation to norhydrocodone (active) and O-demethylation via CYP2D6 to hydromorphone (active). Acetaminophen: hepatic via glucuronidation and sulfation; minor oxidation by CYP2E1 to NAPQI (toxic metabolite).
Renal: 90% (50% as acetaminophen glucuronide, 30% as sulfate, 5% as cysteine, 3% as unchanged drug, 2% as other metabolites); Fecal: <5%
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
10-25% bound to plasma proteins (mainly albumin) at therapeutic concentrations; binding is minimal and not saturable
<20%; primarily binds to albumin.
0.9-1.0 L/kg; indicates distribution into total body water; slightly higher in females and elderly
1.2–1.9 L/kg; suggests extensive distribution into total body water.
Oral: 85-90% (first-pass metabolism reduces bioavailability slightly); Rectal: 80-90%
Oral: 85–95%; rectal: 70–80%.
Contraindicated in severe renal impairment (e GFR <30 m L/min). For moderate impairment (e GFR 30-59 m L/min): extend dosing interval to every 8 hours. Monitor for propoxyphene accumulation.
GFR 30-59 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8 hours; GFR <10 m L/min: Administer every 12 hours; avoid use in severe renal impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce dose by 50% and monitor liver function. Use with caution in class A.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; Child-Pugh Class C: Use not recommended due to hepatotoxicity risk.
Contraindicated in children under 12 years due to risk of respiratory depression. For adolescents 12-18 years: administer as per adult dosing if clinically appropriate; monitor closely.
Children ≥2 years: Hydrocodone 0.1-0.2 mg/kg/dose (max 5 mg/dose) plus acetaminophen 10-15 mg/kg/dose (max 500 mg/dose) orally every 4-6 hours as needed; maximum 5 doses per day.
Start with one tablet every 6 hours due to increased sensitivity and reduced clearance. Maximum: 4 tablets per day. Avoid in patients with renal impairment, respiratory compromise, or concurrent CNS depressants.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours) due to increased sensitivity to opioids and renal clearance decline; monitor for respiratory depression and sedation.
Dipyrone may cause agranulocytosis, a severe and potentially fatal decrease in white blood cells. Use is contraindicated in patients with known hypersensitivity to dipyrone or other pyrazolones.
Risk of addiction, abuse, and misuse; serious, life-threatening or fatal respiratory depression from opioid use; accidental ingestion of acetaminophen can cause acute liver failure; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Risk of agranulocytosis with dipyrone; monitor blood counts. Anticholinergic effects of propantheline (e.g., urinary retention, constipation, blurred vision). Caution in elderly, renal/hepatic impairment, and history of gastrointestinal obstruction.
Addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risk with concomitant use of CNS depressants; severe hypotension; seizures; serotonin syndrome; adrenal insufficiency; hepatotoxicity (acetaminophen overdose); hypersensitivity reactions; constipation; urinary retention; impaired mental/physical abilities.
Hypersensitivity to dipyrone or propantheline,History of agranulocytosis,Bone marrow suppression,Gastrointestinal obstruction,Myasthenia gravis,Narrow-angle glaucoma,Prostatic hypertrophy
Hypersensitivity to hydrocodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction (e.g., paralytic ileus); use of MAO inhibitors (concurrent or within 14 days).
Avoid alcohol and grapefruit juice (may alter tramadol metabolism). High-fat meals may delay absorption but not overall effect. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they may alter metabolism of hydrocodone. Take with food if gastrointestinal upset occurs. Avoid alcohol-containing foods or beverages. No other significant food interactions.
First trimester: Propoxyphene (component of Dolene AP-65) is classified as FDA Pregnancy Category C; animal studies show fetal harm but no adequate human studies. Second/third trimester: Prolonged use may cause opioid withdrawal in neonate (neonatal abstinence syndrome). Acetaminophen (AP-65 component) is generally considered low risk but high doses may be hepatotoxic. Avoid use during pregnancy unless benefit outweighs risk.
First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductus arteriosus and oligohydramnios.
Propoxyphene is excreted in breast milk; M/P ratio approximately 0.5. Low levels in milk; however, due to risk of neonatal opioid toxicity and respiratory depression, caution advised. Acetaminophen is considered compatible with breastfeeding. Consider alternative analgesics.
No data on M/P ratio; use with caution. Low molecular weight may be excreted into breast milk; monitor infant for sedation or respiratory depression.
No specific dose adjustments recommended; however, propoxyphene is generally avoided in pregnancy due to neonatal withdrawal risk. Acetaminophen dose adjustments not typically needed, but monitor for hepatotoxicity, as pregnancy may alter hepatic metabolism. Use lowest effective dose for shortest duration.
No specific dose adjustments required; however, due to increased renal clearance in pregnancy, shortened dosing intervals or higher doses may be needed for adequate analgesia. Monitor clinical response and adjust accordingly.
DOLENE AP-65 is a combination of tramadol (opioid analgesic) and acetaminophen. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcoholism. Maximum daily acetaminophen dose is 4 g; beware of hidden sources. Tramadol may lower seizure threshold; use cautiously in epilepsy or head trauma. CYP2D6 poor metabolizers may have reduced efficacy.
Co-Gesic is a fixed-dose combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g. Hydrocodone is a Schedule II controlled substance with abuse potential. Use with caution in patients with respiratory compromise, COPD, or sleep apnea. Avoid concurrent use with other CNS depressants including alcohol. In opioid-tolerant patients, withdrawal may occur if discontinued abruptly.
Do not exceed 8 tablets per day due to acetaminophen liver toxicity risk.,Avoid alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,May cause drowsiness or dizziness; avoid driving until effects are known.,Report signs of serotonin syndrome (confusion, rapid heart rate, fever) or seizures.,Do not stop abruptly to prevent withdrawal; taper under doctor guidance.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol while taking this medication due to risk of liver damage and increased sedation.,Do not take other medications containing acetaminophen (Tylenol, many cold/flu products) to avoid exceeding the maximum daily dose (4 grams).,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of children and dispose of unused medication properly (take-back programs preferred).,Do not crush or chew extended-release formulations (if applicable).,Report signs of liver injury (yellowing skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOLENE AP-65 vs CO-GESIC, answered by our medical review team.
DOLENE AP-65 is a Opioid Analgesic Combination that works by DOLENE AP-65 is a combination of dipyrone (metamizole) and propantheline. Dipyrone is a non-opioid analgesic and antipyretic that acts centrally and peripherally via inhibition of cyclooxygenase and activation of the endocannabinoid system. Propantheline is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing gastrointestinal motility and spasm.. CO-GESIC is a Opioid Analgesic Combination that works by CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOLENE AP-65 and CO-GESIC depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOLENE AP-65 is: DOLENE AP-65 (propoxyphene napsylate 100 mg and acetaminophen 650 mg). Adult: 1 tablet orally every 4 hours as needed for pain. Maximum: 6 tablets per day.. The standard adult dose of CO-GESIC is: 1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOLENE AP-65 and CO-GESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOLENE AP-65 is classified as Category C. First trimester: Propoxyphene (component of Dolene AP-65) is classified as FDA Pregnancy Category C; animal studies show fetal harm but no adequate human studies. Second/third trim. CO-GESIC is classified as Category C. First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.